{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:19:41Z","timestamp":1793690381467,"version":"4.5.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tzu Chi Med J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/tcmj.tcmj_247_19","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T05:44:14Z","timestamp":1586497454000},"page":"331","source":"Crossref","is-referenced-by-count":8,"title":["Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C"],"prefix":"10.4103","volume":"32","author":[{"given":"Kuo-Chih","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Hsuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1016-3190.282212-1","first-page":"461","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","author":"European","year":"2018","journal-title":"J Hepatol"},{"key":"key-10.4103\/1016-3190.282212-2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12072-015-9629-x","article-title":"A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan","author":"Bennett","year":"2015","journal-title":"Hepatol Int"},{"key":"key-10.4103\/1016-3190.282212-3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"key-10.4103\/1016-3190.282212-4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"key-10.4103\/1016-3190.282212-5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions","author":"Burger","year":"2013","journal-title":"J Hepatol"},{"key":"key-10.4103\/1016-3190.282212-6","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","article-title":", Everson GT.Drug-drug interactions during antiviral therapy for chronic hepatitis C","author":"Kiser","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key-10.4103\/1016-3190.282212-7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/COH.0000000000000185","article-title":"Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection","author":"El-Sherif","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"key-10.4103\/1016-3190.282212-8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/QAI.0000000000001488","article-title":"Brief Report: High Need to Switch cART or comedication with the initiation of DAAs in Elderly HIV\/HCV-coinfected patients","author":"Smolders","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key-10.4103\/1016-3190.282212-9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/apt.13769","article-title":"The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection","author":"Vermehren","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/1016-3190.282212-10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/hiv.12570","article-title":"Management of drug interactions with direct-acting antivirals in Dutch HIV\/hepatitis C virus-coinfected patients: Adequate but not perfect","author":"Smolders","year":"2018","journal-title":"HIV Med"},{"key":"key-10.4103\/1016-3190.282212-11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/MEG.0000000000000152","article-title":"Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: High utilization of drugs with interaction potential","author":"Lauffenburger","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key-10.4103\/1016-3190.282212-12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.15011","article-title":"Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan","author":"Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"key-10.4103\/1016-3190.282212-13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/1060028018766507","article-title":"Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection","author":"Ottman","year":"2018","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/1016-3190.282212-14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcv.2017.01.003","article-title":"Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients","author":"Rodr\u00edguez-Osorio","year":"2017","journal-title":"J Clin Virol"},{"key":"key-10.4103\/1016-3190.282212-15","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral hepatitis C therapy: Pharmacokinetic and pharmacodynamic considerations: A 2019 update","author":"Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/1016-3190.282212-16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40262-018-0710-1","article-title":"Cardiovascular Risk Management and Hepatitis C: Combining Drugs","author":"Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/1016-3190.282212-17","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1128\/AAC.00653-11","article-title":"Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/1016-3190.282212-18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1665-2681(19)30853-1","article-title":"Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin","author":"Kanter","year":"2014","journal-title":"Ann Hepatol"},{"key":"key-10.4103\/1016-3190.282212-19","unstructured":"Liverpool Uo. University of Liverpool Hepatitis drug Interactions Website. Available from: https:\/\/www.hep-druginteractions.org\/. [Last accessed on 2019 July 25]."},{"key":"key-10.4103\/1016-3190.282212-20","unstructured":"Lexi-Comp. Drug-drug Interaction. Riverwoods, IL: Lexicomp, Wolters Kluwer Health, Inc.; 2019."},{"key":"key-10.4103\/1016-3190.282212-21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/2050640616678151","article-title":"The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions","author":"Smolders","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"key-10.4103\/1016-3190.282212-22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cid\/civ973","article-title":"Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort","author":"H\u00f6ner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/1016-3190.282212-23","unstructured":"Harvoni. Available from: https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026675. [Last accessed on 2019 July 25]."},{"key":"key-10.4103\/1016-3190.282212-24","unstructured":"Zepatier. Available from: https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026972. [Last accessed on 2019 July 25]."},{"key":"key-10.4103\/1016-3190.282212-25","unstructured":"Epclusa. Available from: https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027547. [Last accessed on 2019 July 25]."},{"key":"key-10.4103\/1016-3190.282212-26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","article-title":"Statin drug interactions and related adverse reactions: An update","author":"Bellosta","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"key-10.4103\/1016-3190.282212-27","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician's guide to statin drug-drug interactions","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"key":"key-10.4103\/1016-3190.282212-28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/phar.1512","article-title":"Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI\/Liver\/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy","author":"Mohammad","year":"2014","journal-title":"Pharmacotherapy"},{"key":"key-10.4103\/1016-3190.282212-29","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1592\/phco.22.15.1239.33473","article-title":"Individualized drug use assessment in the elderly","author":"Raehl","year":"2002","journal-title":"Pharmacotherapy"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:47:31Z","timestamp":1786733251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_247_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"alternative-id":["282212"],"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_247_19","relation":{},"ISSN":["1016-3190"],"issn-type":[{"value":"1016-3190","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}